TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11807630
Drug: Menatetrenone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (45 mg oral administration)
Study: 19010347
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups measured for glucose, insulin, hsCRP, IL-6, sIL-6R, TNF-alpha, sTNFR1 and sTNFRII.
Study: 16206668
Drug: Psychotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy and Fluoxetine (20mg once a day for 12 weeks)
Study: 16206668
Drug: Regular cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular cardiac medicine therapy
Study: 8057649
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with vindesine (3 mg/m2 weekly x 5, then every 2 weeks x 8) and cisplatin (120 mg/m2 on days 1, 29, 71, 113) plus thoracic irradiation
Study: 8057649
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation
Study: 2522134
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of amlodipine
Study: 2522134
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of amlodipine
Study: 30891721
Drug: moodgym +
Approvals — FDA: no, EMA: no, PMDA: no
Description: moodgym + treatment as usual (TAU)
Study: 28708316
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols supplementation (2.0 g free plant sterols equivalent of palmityl esters daily for 4 weeks)
Study: 25044345
Drug: Resorbable collagen‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resorbable collagen‐based tetracycline fibers (Periodontal Plus AB fibers) adjunct to scaling and root planing
Study: 25044345
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (monotherapy)
Study: 16582045
Drug: Venlafaxine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (titrated from 37.5 to 225 mg per day)
Study: 16582045
Drug: Fluoxetine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (titrated from 20 to 60 mg per day)
Study: 12619027
Drug: Molecular adsorbents
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular adsorbents recirculating system (MARS) treatment for 6 hours
Study: 6379506
Drug: Intramuscular gangliosides
Normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gangliosides (40 mg/d) for 6 months
Study: 29522203
Drug: Pre-EBV <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-EBV < 2300 copies/ml
Study: 29522203
Drug: Pre-EBV ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-EBV ≥ 2300 copies/ml
Study: 15867241
Drug: Temozolomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (200 mg/m2 oral administration)
Study: 12115158
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg twice daily plus nimesulide
Study: 8638531
Drug: Filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (5 micrograms/kg s.c. days 4‐17, 24‐37) during MMM treatment
Study: 29178434
Drug: PF-06273340 400
Normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06273340 400 mg
Study: 29178434
Drug: PF-06273340 50
Normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PF-06273340 50 mg
Study: 27495085
Drug: PEG‐INF‐α2a monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐INF‐α2a monotherapy (group A)
Study: 20651749
Drug: Travoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost/timolol fixed combination (TTFC)
Study: 18341655
Drug: Pentaherbs formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaherbs formulation (PHF)
Study: 8945077
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of oral propafenone administered two hours before pacing (group B)
Study: 30288682
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil 6 mg
Study: 30288682
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil 20 mg
Study: 30288682
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil (various doses: 6, 20, 40, 60, 80 mg)
Study: 30288682
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil (various doses)
Study: 24854817
Drug: Self-reported unhealthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported unhealthy weight loss behaviors (e.g., fasting, purging)
Study: 21863477
Drug: Polymeric nanoparticles
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric nanoparticles containing celecoxib dosed orally in aqueous suspensions
Study: 21863477
Drug: Commercial capsules
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial capsules of celecoxib
Study: 21863477
Drug: Nanoparticle suspensions
Normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanoparticle suspensions
Study: 17980251
Drug: AZD6140 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 90 mg twice a day
Study: 17980251
Drug: AZD6140 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 180 mg twice a day
Study: 17980251
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once a day
Study: 17980251
Drug: AZD6140 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 (both doses) in clopidogrel pretreated patients
Study: 15793737
Drug: Continuing antibiotics
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing antibiotics
Study: 15793737
Drug: Discontinuing antibiotics
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing antibiotics
Study: 12377396
Drug: Acamprosate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (2 g/d)
Study: 22610930
Drug: Doxycycline and
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline and Amoxicillin
Study: 899774
Drug: Diazepam rectally
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam rectally as a solution (0.7 mg/kg)
Study: 899774
Drug: Diazepam rectally
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam rectally by suppository (5 mg)
Study: 31283865
Drug: Quetiapine extended-release
Normalized name: Quetiapine Extended-Release Tablets
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine extended-release (QUEXR300), 300 mg/d
Study: 31283865
Drug: Olanzapine (OLA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (OLA), 5-20 mg/d
Study: 23784548
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride 0.06 mg/kg
Study: 23784548
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride 0.125 mg/kg
Study: 21700683
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice a week (biw)
Study: 21700683
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once a week (qw)
Study: 21700683
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg biw and qw
Study: 17173662
Drug: 1 kcal/minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 kcal/minute nutrient infusion
Study: 17173662
Drug: 2 kcal/minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 kcal/minute nutrient infusion
Study: 2580383
Drug: ERU-capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERU-capsules
Study: 27530663
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 500 mg given 2 hours or more prior to antivenom therapy (Group A)
Study: 27530663
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone at the time of antivenom therapy (Group B)
Study: 19884643
Drug: Bortezomib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1 mg/m² x 4) and melphalan (200 mg/m²) as conditioning regimen (Bor‐HDM)
Study: 12151873
Drug: Candesartan (AT1-antagonist)
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (AT1-antagonist)
Study: 10214783
Drug: Ciprofloxacin (CIP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (CIP; 500 mg twice daily for 10 days, placebo for 4 days)
Study: 10214783
Drug: Clarithromycin (CLARI;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (CLARI; 500 mg twice daily for 14 days)
Study: 2170309
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with daily cDDP (arm III)
Study: 6104933
Drug: Continuous application
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous application of Diazepam, Flunitrazepam, and Benzoctamin in 500 ml physiological NaCl-Solution
Study: 6104933
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of sedatives (implied control)
Study: 31775854
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia (TIVA) during surgery
Study: 21385086
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) - five 50-minute sessions over a 10-week period
Study: 21385086
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no OMT, sham treatment, or physical therapy)
Study: 19177862
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine plus 1 microg mL(‐1) of sufentanil in continuous infusion at a rate of 7 mL h(‐1)
Study: 19177862
Drug: 0.0625% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625% bupivacaine plus 1 microg mL(‐1) of sufentanil in continuous infusion at a rate of 7 mL h(‐1)
Study: 19177862
Drug: Rescue analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesia with intravenous ketoprofen and morphine
Study: 8509823
Drug: Intra-arterial mannitol
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial mannitol infusion (50 ml of 20% mannitol at 50 ml/min) prior to ACNU and CDDP (100 mg/body at 20 mg/min)
Study: 8509823
Drug: ACNU and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACNU and CDDP (100 mg/body at 20 mg/min) without mannitol infusion
Study: 2862516
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and acyclovir combination therapy
Study: 29362795
Drug: Massed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massed therapy (10 sessions over 2 weeks)
Study: 29362795
Drug: Minimal-contact control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-contact control (MCC; telephone calls from therapists, once weekly for 4 weeks)
Study: 29362795
Drug: Spaced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced therapy (10 sessions over 8 weeks)
Study: 29362795
Drug: Present-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered therapy (PCT; 10 sessions over 8 weeks)
Study: 25594166
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (0.3 g/d)
Study: 25594166
Drug: EPA (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (1.3 g/d)
Study: 25594166
Drug: EPA+α-lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+α-lipoic acid (1.3 g/d + 0.3 g/d)
Study: 22406434
Drug: Sodium nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitrate (0.15 mmol/kg or 12.7 mg/kg) in 150 ml water
Study: 18592783
Drug: Weekly nedaplatin
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly nedaplatin (30 mg/mm2/time, once a week, total 150 mg/mm2/5 weeks) combined with radiation therapy (50 Gy-52 Gy/25-27 fractions with central shielding after 30-32 Gy and high-dose rate intracavitary irradiation 24-30 Gy/4-6 fractions to point A)
Study: 18592783
Drug: Weekly nedaplatin
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly nedaplatin combined with radiation therapy
Study: 15977094
Drug: Bupivacaine-morphine (BM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-morphine (BM)
Study: 12646507
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber (13.5 g/day)
Study: 12646507
Drug: Low fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fiber (2.0 g/day)
Study: 3391002
Drug: Verapamil, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 120 mg every 8 hours for 7 days
Study: 3391002
Drug: Diltiazem, 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 90 mg every 8 hours for 7 days
Study: 3391002
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg every 8 hours for 7 days
Study: 3391002
Drug: Control (theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (theophylline alone, 5 mg/kg)
Study: 1054222
Drug: Laminar air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminar air flow room reverse isolation with oral nonabsorbable antibiotics (LAF plus A)
Study: 1054222
Drug: Routine hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hospital ward care with antibiotics (W plus A)
Study: 23242843
Drug: Propofol TCI
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TCI at 5 μg/mL for 2 min followed by 3 μg/mL
Study: 23242843
Drug: Sevoflurane 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 5% at inhaled concentration
Study: 21526413
Drug: Pharmacist-initiated medication
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmacist-initiated medication use review
Study: 17877128
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy (ET)
Study: 11809183
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin with oral prednisone
Study: 11809183
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone with oral prednisone
Study: 9466467
Drug: Immunomodulatory agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory agents
Study: 9466467
Drug: Clinical trials
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trials of agents based on clinically flawed models
Study: 8056888
Drug: 10% benzoyl
Normalized name: BENZOYL PEROXIDE 10 g in 100 g TOPICAL SOAP [Dermaharmony 10% Benzoyl Peroxide Cleansing Bar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% benzoyl peroxide gel applied once a day for 7 days before surgery
Study: 2972270
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride therapy
Study: 15830485
Drug: Cephalothin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (1 g intravenous dose) over 120, 30, and 3 min
Study: 15830485
Drug: Cefoxitin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1 g intravenous dose) over 120, 30, and 3 min
Study: 15830485
Drug: Probenecid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (1 g intravenous infusion) prior to cephalothin
Study: 15830485
Drug: Probenecid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (1 g intravenous infusion) prior to cefoxitin
Study: 18335515
Drug: MYO-029 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYO-029 at 1 mg/kg
Study: 18335515
Drug: MYO-029 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYO-029 at 3 mg/kg
Study: 18335515
Drug: MYO-029 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYO-029 at 10 mg/kg
Study: 18335515
Drug: MYO-029 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYO-029 at 30 mg/kg
Study: 18335515
Drug: MYO-029 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYO-029 (all doses)
Study: 11796346
Drug: Didanosine encapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine encapsulated enteric bead formulation (400 mg) with indinavir (800 mg)
Study: 11796346
Drug: Didanosine encapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine encapsulated enteric bead formulation (400 mg) with ketoconazole (200 mg)
Study: 11796346
Drug: Didanosine encapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine encapsulated enteric bead formulation (400 mg) with ciprofloxacin (750 mg)
Study: 23278176
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C (1400 mg) and E (800 mg) supplementation
Study: 20492527
Drug: Topical OLEOZON(®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical OLEOZON(®), applied two times per day for 3 months
Study: 20492527
Drug: Ketoconazole cream
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole cream 2%, applied two times per day for 3 months
Study: 20492527
Drug: Topical OLEOZON(®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical OLEOZON(®)
Study: 19652547
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in the vaccine trial
Study: 12680737
Drug: Flunitrazepam (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1.2 mg)
Study: 10760556
Drug: Unilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral ECT with antidepressant drugs (Group-1)
Study: 10760556
Drug: Unilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral ECT with drug placebo (Group-2)
Study: 12097668
Drug: Leucine infusion
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine infusion at 4.1 mg/(kg. 12 h)
Study: 12097668
Drug: Leucine infusion
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine infusion at 6.6 mg/(kg. 12 h)
Study: 12097668
Drug: Leucine infusion
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine infusion at 8.3 mg/(kg. 12 h)
Study: 12097668
Drug: Leucine infusion
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine infusion (all rates)
Study: 9827735
Drug: 20-minute EMLA
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute EMLA cream
Study: 9827735
Drug: 20-minute placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute placebo cream
Study: 2571326
Drug: Betaxolol hydrochloride
Normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaxolol hydrochloride ophthalmic solution
Study: 2571326
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate ophthalmic solution
Study: 22295
Drug: Droperidol premedication
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol premedication (0.3 to 0.5 mg/kg)
Study: 30357066
Drug: Pure tone
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure tone audiometric tests administered by an audiologist
Study: 11472284
Drug: Propofol injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol injection without iv carrier fluid
Study: 11472284
Drug: Propofol injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol injection with iv carrier fluid
Study: 9531581
Drug: Escherichia coli‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli‐derived GM‐CSF (5 micrograms/kg/d by 6‐hour intravenous infusion) during induction chemotherapy.
Study: 9531581
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during induction chemotherapy.
Study: 1363660
Drug: Bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (10 mg o.d.)
Study: 1363660
Drug: Celiprolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (400 mg o.d.)
Study: 1363660
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg o.d.)